Evaluating BTX-A51 for advanced solid tumors and breast cancer
Official title: An Open Label, Escalating Multiple Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX A51 Alone and in Combination With Fulvestrant in Subjects With Advanced Solid Tumors and Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer
Run by Edgewood Oncology Inc. · NCT04872166 · Data updated 2026-11-12
This study is testing a new treatment called BTX-A51 for people with advanced solid tumors and metastatic breast cancer to see how safe it is and if it works better alone or with another medication.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 112 (estimated) |
| Sponsor | Edgewood Oncology Inc. Industry-sponsored |
| Drugs / interventions | chemotherapy, immunotherapy, radiation, prednisone |
| Locations | 6 sites (Lake Mary, Florida and 5 other locations) |
| Status | Recruiting |
| Started | June 7, 2021 |
| Main results expected | May 2026 |
| Study ends | May 2027 |
| Registry record updated | January 30, 2025 |
| Trial ID | NCT04872166 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with incurable or metastatic solid tumors that are refractory to standard therapies.
✕Probably not a fit
Patients with tumors amenable to standard therapies or those who do not meet the eligibility criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter, open-label, nonrandomized Phase 1 trial aims to assess the safety, toxicity, pharmacokinetics, and preliminary efficacy of BTX-A51, both alone and in combination with fulvestrant, in patients with advanced solid tumors and metastatic breast cancer. The study will involve a dose escalation approach to determine the maximum tolerated dose and recommended Phase 2 dose, with participants receiving the treatment on a weekly schedule. The trial will consist of multiple phases, focusing on patients who have exhausted standard treatment options.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for patients with advanced solid tumors and metastatic breast cancer who have limited alternatives.
How similar studies have gone: While this approach is novel, similar studies evaluating new treatments for advanced solid tumors have shown promise in the past.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Demonstration of understanding and voluntarily signing of an informed consent form * Age ≥ 18 years * Histologically or cytologically documented, incurable or metastatic solid tumor that is refractory to or intolerant of all standard therapy or for which no standard therapy is available * Phase 1b and 1c only: Histologically confirmed diagnosis of ER+, HER2- mBC not amenable to resection or radiation therapy with curative intent. * Measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). * Adequate organ function * Females of childbearing age must not be pregnant at time of Screening/beginning of treatment and agree to either abstain from sexual intercourse or use highly effective methods of contraception (for up to 3 months after last dose of study drug) * Males sexually active with a woman of childbearing age must agree to use barrier method of birth control during and after the study (up to 3 months after last dose of study drug) Exclusion Criteria: * Life expectancy \<3 months, as determined by the Investigator. * Treatment with any local or systemic antineoplastic therapy (including chemotherapy, hormonal therapy, or radiation) within 3 weeks prior to first dose of BTX-A51 * Chronic use of corticosteroids in excess of 10 mg daily of prednisone or equivalent within 4 weeks prior to first dose of BTX-A51 * Major trauma or major surgery within 4 weeks prior to first dose of BTX-A51. * Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤1 except for alopecia or Grade ≤2 immunotherapy-related thyroid toxicity. * History of, or known, central nervous system (CNS) disease involvement, or prior history of NCI CTCAE Grade ≥3 drug-related CNS toxicity. * Clinically significant cardiac disease * Active uncontrolled systemic fungal, bacterial, mycobacterial, or viral infection * Known positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) * Active hepatitis C virus (HCV) or hepatitis B virus (HBV) * Second primary malignancy that has not been in remission for greater than 3 years * Any serious underlying medical (e.g., pulmonary, renal, hepatic, gastrointestinal, or neurological) or psychiatric condition (e.g., alcohol or drug abuse, dementia or altered mental status) or any issue that would limit compliance with study requirements * Pregnant, lactating, or breastfeeding. * Participation or plans to participate in another interventional clinical study.
Where it's running
-
Florida Cancer Specialists
Lake Mary, Florida, United States Recruiting -
Florida Cancer Specialists
Sarasota, Florida, United States Recruiting -
SCRI Oncology Partners
Nashville, Tennessee, United States Recruiting -
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States Recruiting -
The Linder Research Center at The Christ Hospital
Cincinnati, Ohio, United States Completed -
Tennessee Oncology, PLLC
Nashville, Tennessee, United States Completed
Study contacts
- Study coordinator: Zung Thai, MD
- Email: zung@edgewoodonc.com
- Phone: 415-225-9338
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing ERX-315 in patients with advanced solid tumors
This study is testing a new treatment called ERX-315 to see if it is safe and effective for people with advanced solid tumors that haven't responded to other therapies.
-
BGB-43395 treatment for advanced breast cancer and other solid tumors
This study is testing a new treatment called BGB-43395 for people with advanced breast cancer and other solid tumors to see if it works better alone or with other medications.
-
PRT13722 in advanced HR+/HER2- breast cancer
This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.
-
Personalized treatment after endocrine therapy failure in metastatic breast cancer
The study tests whether using a patient’s fresh tumor sample to try different drugs outside the body can help pick the next therapy for hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on endocrine therapy.
-
SGT003 in people with advanced solid tumors
This early-phase study tests SGT003 in adults with advanced solid tumors to see if it is safe and tolerable and to get a first look at how it behaves in the body and any early signs of benefit.
-
YSCH-01 Nebulized Therapy for Lung Metastases in NSCLC and Advanced Solid Tumors
A first-in-human, early-phase study tests a nebulized therapy called YSCH-01 to see if it is safe and shows any signs of benefit for adults with NSCLC or other cancers that have spread to the lungs.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.